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Abstract
Background: In spite of excellent cure rates for prostate cancer patients with favorable tumor characteristics,
patients with unfavorable characteristics after radical prostatectomy are still at a significantly increased risk of
tumor progression. Early adjuvant hormonal therapy (AHT) has been shown to be of prognostic benefit in these
patients. Unfortunately initiation and duration of early AHT in the individual patient is based on statistic data. PSA,
as the standard prostate marker is neither able to reliably indicate minimal residual tumor disease in the early
postoperative phase, nor can it be used for therapy monitoring due to the suppressive effect of hormonal therapy
on PSA production. Promoter hypermethylation of the detoxifying glutathione-S-transferase P1 gene (GSTP1-HM)
has been shown to be the most common DNA alteration of primary prostatic carcinoma which, when used as a
marker, is supposed to be able to overcome some of the disadvantages of PSA. However until now information
on the impact of hormonal therapy on the detection of GSTP1-HM is lacking. The purpose of our study was to
assess the impact of endocrine therapy on the detection of GSTP1-HM by methylation-specific PCR (MSP) in
prostate cancer.
Methods: Paraffin embedded tumor samples from the radical prostatectomy (RP) specimens from 15 patients
after hormonal therapy (HT) (mean 8 months) were assessed by MSP. In 8 of the patients the GSTP-1 status of
the tumors before HT was assessed on the corresponding initial diagnostic biopsies.
Results: Following HT MSP showed GSTP1-HM in 13/15 of the RP specimens. In two patients analysis of the RP
specimens failed to show GSTP1-HM. All initial tumor samples (8/8 biopsy specimens) showed GSTP1-HM,
including both patients negative for GSTP1 HM in the corresponding RP specimen.
Conclusion: In most cases hormonal therapy appears to not alter GSTP1 HM detection. However the change
from a positive to a negative GSTP1 HM status in a subset of the patients may point to an, at least partial androgen
dependency. Further studies on a larger cohort of patients are necessary to assess its frequency and the exact
hormonal interactions.
Published: 27 June 2006
BMC Urology 2006, 6:15 doi:10.1186/1471-2490-6-15
Received: 08 March 2006
Accepted: 27 June 2006
This article is available from: http://www.biomedcentral.com/1471-2490/6/15
© 2006 Köllermann et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Urology 2006, 6:15 http://www.biomedcentral.com/1471-2490/6/15
Page 2 of 6
(page number not for citation purposes)
Background
In spite of a stage migration towards early tumor stages
and a decreased prostate cancer mortality rate, attributa-
ble to the wide spread use of PSA [1], a significant propor-
tion of patients after putative curative radical
prostatectomy still presents with unfavorable tumor char-
acteristics (high Gleason score, positive surgical margins,
non organ confined tumors) which are indicative for a
high risk of tumor progression [2]. Recent data from the
EPC Program study group indicate that early early adju-
vant hormonal therapy (AHT) after radical prostatectomy
is of prognostic benefit in these patients [3]. Therefore an
increase in the number of patients submitted to early AHT
has to be expected. The submission of patients to AHT,
however, is completely based on statistic data. Biomarkers
which are able to indicate the need for early AHT and
allow therapy monitoring in the individual patient are
needed to avoid overtreatment, unnecessary side effects
and costs. Unfortunately in this respect PSA, as the stand-
ard prostate marker, is of very limited value. Neither is it
able to reliably indicate minimal residual tumor disease
in the early postoperative phase, nor can it be used for
therapy monitoring due to the suppressive effect of hor-
monal therapy on PSA production. GSTP1-CpG island
hypermethylation (GSTP1-HM) has been shown to be a
promising new marker of prostate cancer, which is sup-
posed to be able to overcome some of the disadvantages
of PSA. Promoter hypermethylation of the detoxifying
glutathione-S-transferase P1 gene (GSTP1) is the most
common DNA alteration of primary prostatic carcinoma
and has already been assessed in prostatic tissue, lymph
nodes and bodily fluids of prostate cancer patients by our
own group and others [4-8]. However until now informa-
tion on the impact of hormonal therapy on the detection
of GSTP1-HM is lacking. In a pilot study we analyzed
tumor tissue from a highly selective cohort of patients
before and after long-term neoadjuvant hormonal ther-
apy for the presence of GSTP1-HM by methylation spe-
cific PCR (MSP).
Methods
Representative, paraffin-embedded tumor samples of the
radical prostatectomy specimens with a tumor content of
at least 50% from 15 patients were studied by MSP. Probe
retrieval was done in agreement with the Helsinki Decla-
ration. Institutional review board approval (Ethics com-
mittee of the Charité – Universitätsmedizin Berlin) was
obtained for this study. All patients signed a consent form
approved by the Committee on Human Rights in
Research at our institution.
All patients have been submitted to prior complete andro-
gen deprivation therapy until PSA nadir (mean 8
months). In 8 of the patients tumor containing, paraffin
embedded prostate biopsies before the initiation of hor-
monal therapy (HT) were obtained for MSP. In the
remainder of the patients biopsy material of the untreated
tumors could not be obtained due to tissue loss after rou-
tine pathological work up (small tumor foci, loss during
the recutting process, immunohistochemistry). Several 5
microm thick recuts were obtained from each paraffin
block. One sections of each block was stained with H&E
to confirm the presence of prostate cancer in the recuts
prior to MSP. The remaining unstained sections were used
for DNA extraction as follows: Sections were deparaffin-
ized using 100% xylene followed by 100% ethanol. The
pellet was then resuspended in a lysis buffer containing
proteinase K. DNA was isolated by the QIAamp DNA Mini
Kit (QIAgen, Hilden, Germany). Using the CpGenome
DNA Modification Kit (Intergen, Oxford, UK), DNA was
modified by bisulfite treatment for the detection of meth-
ylated CpG residues, according to the manufacturer's rec-
ommendations. GSTP1 promoter hypermethylation, i.e.
the presence of methylated CpGs in the promoter region
was qualitatively assessed by MSP [5]. The target region
for MSP lies within the GSTP1 promoter. GSTP1 promoter
sequences were used for the methylated reaction (92-base
pair product with blue fluorescence, representing neoplas-
tic DNA; (forward primer: 5'-6FAM-TTC GGG GTG TAG
CGG TCG TC-3'; reverse primer: 5'-GCC CCA ATA CTA
AAT CAC GAC G-3') and for the unmethylated reaction a
99-base pair product with green fluorescence, represent-
ing normal unmethylated DNA was detectable (forward
primer: 5'-HEX-GAT GTT TGG GGT GTA GTG GTT GTT-
3'; reverse primer: 5'-CCA CCC CAA TAC TAA ATC ACA
ACA-3') [7]. MSP (15 minutes at 95°C; 35 cycles at 59°C
for 30 seconds; 72°C for 30 seconds; and 95°C for 30 sec-
onds) was performed in a 10-μl reaction volume using
HotStar Taq Master Mix (QIAgen, Hilden, Germany). The
MSP products from the unmethylated and methylated
reactions were analyzed by laser fluorescence on an auto-
mated gene sequencer using Gene Scan software, as
described elsewhere [5]. In each case with a negative find-
ing MSP was performed twice. Negative (water blank) and
positive (DNA from LNCaP cells with a known GSTP1
promoter hypermethylation) controls were included in
the experiments.
Results
The relevant clinical data of the patients are shown in
table 1. Mean age at the time of diagnosis was 65 years
(range 57 – 73). Median initial PSA was 14.4 ng/ml (range
6.4 – 63.7 ng/ml).
MSP showed GSTP1 promoter hypermethylation (GSTP1
HM) in 13/15 of the radical prostatectomy samples. The
majority of the tumors showed moderate regression
(regression grade 2). Only two patients showed minor,
one showed major regressive tumor changes after HT. In
two RP specimens MSP failed to show GSTP1-HM (fig. 2).BMC Urology 2006, 6:15 http://www.biomedcentral.com/1471-2490/6/15
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Both tumors showed moderate regressive change (table
1).
All prostate tumor biopsies obtained prior to HT, showed
GSTP1-HM (8/8). Interestingly this includes both patients
in whom MSP of the RP specimens failed to show GSTP1-
HM (table 1, fig. 1).
Discussion
Since the knowledge about the close association of GSTP1
CpG island hypermethylation and prostatic carcinogene-
sis [9], an increasing number of studies evaluated its
potential as prostate cancer biomarker. Its feasibility for
diagnosis and staging as well as its prognostic value have
been intensively assessed in prostate tissue (biopsies and
surgical specimens), biopsy washings, ejaculates, blood,
urine and lymph nodes by our group and others [4-6,8].
Continuous technical improvements from southern blot
analysis to polymerase chain reaction (PCR), which was
further improved by the introduction of the methylation
specific technique either qualitative or quantitative up to
multigene methylation analysis lead to a steady increase
of the diagnostic and prognostic power [10-13]. The pos-
sibility to detect GSTP1-HM in the blood serum from
prostate cancer patients [5,7] and recent reports about the
prognostic significance of its detection [14] indicate, that
the determination of GSTP1-HM in blood serum may rep-
resent a very promising tool for the follow-up of prostate
cancer patients. In face of an expected increase in early
AHT and the above-mentioned limitations of PSA, the
determination of GSTP1-HM in the blood serum appears
to be very promising. However, at least to our knowledge,
information on the impact of hormonal therapy on its
detection is lacking.
In most of the cases analyzed (13/15), MSP was able to
detect GSTP1-HM after prolonged neoadjuvant hormonal
therapy. However in two patients we failed to demon-
strate GSTP1-HM after HT. The presence of GSTP1-HM in
the initial biopsies of both patients indicates, that HT may
influence the detection of GSTP1-HM in a subset of
patients.
In addition to the supposed hormonal interaction other
possible explanations for our findings have to be critically
discussed.
First of all the lack of GSTP1 HM may be attributable to
technical problems (false negative MSP). Although this
cannot be excluded completely, several facts argue
strongly against this assumption:
1. Prior to DNA analysis the presence of tumor (at least
50% of the sample) in the RP sample was controlled by
microscopic assessment of the corresponding HE stained
slides (see methods),
2. Both MSP negative samples were analyzed twice,
3. Internal negative (water blank) and positive controls
(DNA from LNCaP cells) were always included in the
experiments.
4. Unmethylated GSTP1 promoter sequences were seen in
both specimens.
Furthermore one has to take into account the possibility
that both tumors primarily lacked GSTP1 HM. However
the presence of GSTP1 HM in the corresponding tumor
Table 1: Findings in the prostate cancer cohort (n = 15) showing pT-stage, final Gleason score, grade of tumor regression according to 
Helpap et al [15] in correlation to GSTP1 HM status in the initial prostate biopsy and the corresponding radical prostatectomy 
specimens after neoadjuvant hormonal therapy.n.m. = no material, pos = positive
Case pT-stage Final Gleason score RG Biopsy GSTP1 RP GSTP1
1281 n . m . p o s
2272 n . m . p o s
3272 n . m . p o s
4282 p o s p o s
5262 n . m . p o s
6282 p o s p o s
7272 n . m . p o s
8262 n . m . p o s
9263 p o s p o s
10 2 6 2 n.m. pos
1 1 262 p o s p o s
1 2 272 p o s p o s
1 3 272 p o s n e g
1 4 262 p o s n e g
1 5 271 p o s p o sBMC Urology 2006, 6:15 http://www.biomedcentral.com/1471-2490/6/15
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biopsies prior to hormonal therapy argues strongly
against this assumption.
Due to the general problem to obtain prostate cancer tis-
sue samples before and after hormonal therapy even in
cooperation with a specialized center of uropathology
(B.H) the number of specimens analyzed in our study
admittedly is very small and the results therefore only
allow to conclude that androgen ablation therapy appears
to influence GSTP1 HM. To assess the true extent further
studies on larger cohorts of patients are necessary.
Conclusion
In most cases hormonal therapy appears to not alter
GSTP1 HM detection. However the change from a positive
to a negative GSTP1 HM status in a subset of our patients
may point to an, at least partial androgen dependency.
Further studies on larger cohorts of patients are manda-
tory to assess its frequency and the exact hormonal inter-
actions.
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a) Prostate biopsy showing well differentiated adenocarcinoma of the prostate prior to neoadjuvant antiandrogen therapy  (H&E staining) Figure 1
a) Prostate biopsy showing well differentiated adenocarcinoma of the prostate prior to neoadjuvant antiandrogen therapy 
(H&E staining). b) GSTP1 promoter methylation analysis of the tumor displaying both methylated (M, 92-base pairs (bp) prod-
uct, blue fluorescence; tumor DNA) and unmethylated (UN, 99-bp product, green fluorescence) GSTP1 promoter sequences.BMC Urology 2006, 6:15 http://www.biomedcentral.com/1471-2490/6/15
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